Comparative Pharmacology
Head-to-head clinical analysis: HEPSERA versus LIVTENCITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPSERA versus LIVTENCITY.
HEPSERA vs LIVTENCITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclic nucleotide analog of adenosine monophosphate; inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate dATP, causing DNA chain termination after incorporation into viral DNA.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
10 mg orally once daily.
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 6-9 hours in patients with normal renal function. In renal impairment, half-life is prolonged (up to 18 hours in moderate impairment, >30 hours in severe impairment). Steady-state is achieved within 5-7 days.
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Primarily renal; 70-90% of an oral dose is excreted unchanged in urine via active tubular secretion and glomerular filtration. Biliary/fecal elimination accounts for <5%.
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Category C
Category C
Antiviral
Antiviral